1. Contralateral prophylactic mastectomy and survival: report from the National Cancer Data Base, 1998–2002

   • Katharine Yao
   • David J. Winchester
   • Dezheng Huo

   Review 12 November 2013 Pages: 465 - 476

   

2. DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells

   • Johanna Tuomela
   • Jouko Sandholm
   • Katri S. Selander

   Preclinical Study 10 November 2013 Pages: 477 - 487

   

3. Role of HGF in obesity-associated tumorigenesis: C3(1)-T_Ag mice as a model for human basal-like breast cancer

   • Sneha Sundaram
   • Alex J. Freemerman
   • Liza Makowski

   Preclinical Study 12 November 2013 Pages: 489 - 503

   

4. A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation

   • Xianxiao Zhou
   • Bailiang Li
   • Zheng Guo

   Preclinical study 20 November 2013 Pages: 505 - 514

   

5. Single-strand selective monofunctional uracil-DNA glycosylase (SMUG1) deficiency is linked to aggressive breast cancer and predicts response to adjuvant therapy

   • Tarek M. A. Abdel-Fatah
   • Nada Albarakati
   • Srinivasan Madhusudan

   Preclinical study 20 November 2013 Pages: 515 - 527

   

6. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer

   • Kristina P. Sørensen
   • Mads Thomassen
   • Torben A. Kruse

   Preclinical Study 21 November 2013 Pages: 529 - 536

   

7. Tamoxifen selects for breast cancer cells with mammosphere forming capacity and increased growth rate

   • Diego Raffo
   • Damian E. Berardi
   • Marina Simian

   Preclinical study 21 November 2013 Pages: 537 - 548

   

8. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

   • Xiaosong Chen
   • Guolin Ye
   • Kunwei Shen

   Clinical trial 14 November 2013 Pages: 549 - 558

   

9. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients

   • Kyung Lan Ko
   • In Suk Shin
   • Eun Sook Lee

   Clinical trial 14 November 2013 Pages: 559 - 567

   

10. Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide

    • Harriet Johansson
    • Bernardo Bonanni
    • Andrea DeCensi

    Clinical trial 17 November 2013 Pages: 569 - 578

    

11. Comparing the outcome between multicentric and multifocal breast cancer: what is the impact on survival, and is there a role for guideline-adherent adjuvant therapy? A retrospective multicenter cohort study of 8,935 patients

    • R. Wolters
    • A. Wöckel
    • For the BRENDA Study Group

    Clinical trial 21 November 2013 Pages: 579 - 590

    

12. Radiotherapy in implant-based immediate breast reconstruction: risk factors, surgical outcomes, and patient-reported outcome measures in a large Swedish multicenter cohort

    • Max Eriksson
    • Lotta Anveden
    • Jana de Boniface

    Clinical Trial 21 November 2013 Pages: 591 - 601

    

13. Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

    • Sara A. Hurvitz
    • Deepa Lalla
    • Susan D. Mathias

    Epidemiology Open access 12 November 2013 Pages: 603 - 609

14. Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral

    • Sarah L. Ingham
    • Matthew Sperrin
    • D. Gareth R. Evans

    Epidemiology 20 November 2013 Pages: 611 - 618

    

15. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis

    • Liang Wu
    • Fengliang Wang
    • Cheng Lu

    Epidemiology 21 November 2013 Pages: 619 - 627

    

16. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors

    • Henry G. Kaplan
    • Judith A. Malmgren
    • Gregory S. Calip

    Epidemiology 22 November 2013 Pages: 629 - 636

    

17. Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis

    • Wei Chen
    • Haiping Song
    • Xiaoping Miao

    Epidemiology 22 November 2013 Pages: 637 - 644

18. Cardiovascular disease among breast cancer survivors: the call for a clinical vascular health toolbox

    • Lynnette M. Jones
    • Lee Stoner
    • Blair McLaren

    Brief Report 16 November 2013 Pages: 645 - 653

    

19. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer

    • Denise A. Yardley
    • Lowell Hart
    • Howard Burris

    Brief Report 21 November 2013 Pages: 655 - 665

    

20. Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines

    • Abigail Silva
    • Garth H. Rauscher
    • Carol Estwing Ferrans

    Brief Report 22 November 2013 Pages: 667 - 672

21. Acknowledgement of reviewers 2013

    Events 29 November 2013 Pages: 673 - 680